CGRP-Targeted Migraine Prevention as a First-Line Option: A Family Medicine Prescribing Framework

Introduction

Why “first-line” now means three different things

For years, many US treatment pathways positioned CGRP-targeted prevention after failure of two or more older medications. The 2024 AHS position statement changed the clinical sequence: a CGRP monoclonal antibody or preventive gepant may be offered alongside established first-line options, and treatment should not be conditioned on prior failure of nonspecific preventives. [1]

The 2025 ACP guideline reached a different operational conclusion for a narrower population. In nonpregnant adults receiving outpatient treatment for episodic migraine, ACP suggests starting with monotherapy using metoprolol or propranolol, valproate, venlafaxine, or amitriptyline. It places atogepant, rimegepant, or a preventive CGRP monoclonal antibody after intolerance of or inadequate response to that first group, and topiramate after the CGRP-targeted group. ACP explicitly incorporated economic evidence and patient preferences when clinical net-benefit differences were unclear. [2]

A useful primary 5rf[care distinction

• First-line eligible: A therapy can be selected without a medically necessary failure of another preventive.
• Best first prescription: The therapy best fits this patient’s migraine burden, comorbidities, preferences, reproductive context, adherence pattern, and safety profile.
• First covered: The health plan will authorize the therapy, and the patient can obtain it at an acceptable out-of-pocket cost.

Table 1. How to reconcile the major prescribing frameworks

Framework	Core position	Family medicine interpretation
AHS 2024	CGRP-targeted therapies are a first-line option alongside established choices; prior failure is not required. [1]	Use clinical fit and shared decision-making rather than an automatic step-failure rule.
ACP 2025	For nonpregnant adults with episodic migraine, use selected established oral monotherapy first, then CGRP-targeted monotherapy after inadequate response or intolerance. [2]	A value-conscious pathway is reasonable when cost, access, or a useful comorbidity match favors an established oral drug.
IHS 2024 and 2025	Offer prevention when frequency, impact, poor acute response, or frequent acute-drug use warrants it; consider earlier prevention, but do not claim proven disease modification. [3,4]	Do not wait for chronification when the burden already justifies prevention, but set evidence-based expectations.

These statements do not require a forced choice between societies. AHS addresses whether CGRP-targeted treatment is clinically acceptable as an initial option. ACP addresses a cost- and preference-sensitive sequence in a defined episodic-migraine population. IHS provides a global framework for deciding when to start prevention and how to evaluate response. A family medicine prescription can be faithful to all three when the rationale is explicit.

Step 1: Confirm migraine and establish a defensible baseline

A first-line debate is irrelevant if the headache phenotype is wrong. Migraine without aura is defined by recurrent 4- to 72-hour attacks with characteristic pain features and associated nausea, vomiting, photophobia, or phonophobia. [5] Chronic migraine requires headache on at least 15 days per month for more than 3 months, with migraine features on at least 8 days per month. [6]

Medication-overuse headache can coexist with episodic or chronic migraine. The general ICHD-3 definition requires headache on at least 15 days per month plus regular overuse of acute or symptomatic headache medication for more than 3 months; the day threshold depends on the medication class. [7] Do not delay all preventive treatment until overuse is completely resolved. Document acute-treatment days, counsel on limits, and manage withdrawal or reduction in parallel with prevention when clinically appropriate. [3,7]

At the prescribing visit, record:

• Monthly headache days and monthly migraine days, preferably from a 4-week diary.
• Number of days using triptans, combination analgesics, opioids, nonsteroidal anti-inflammatory drugs, acetaminophen, or gepants for acute treatment.
• Attack duration, associated symptoms, aura status, and the degree of work, family, sleep, and activity impairment.
• A reproducible disability measure such as HIT-6 or MIDAS when practical.
• Previous preventive drugs, dose, duration, benefit, adverse effects, and the reason each was stopped.
• The patient’s treatment goal, such as fewer disabling days, reliable work attendance, less acute-medication use, or reduced unpredictability.
• A focused neurologic examination and evaluation for secondary-headache warning features before treating a new, changing, or atypical syndrome as routine migraine.

The International Headache Society recommends preventive pharmacotherapy when there are at least 4 monthly headache days or when migraine has meaningful life impact, acute treatment is ineffective or poorly tolerated, or acute medication is being used frequently. [3] Frequency is therefore a trigger, not the sole qualification. A patient with fewer but prolonged or disabling attacks may still have a strong preventive indication.

Step 2: Decide whether this patient belongs in a CGRP-first lane

A CGRP-targeted drug is especially reasonable as the initial preventive prescription when several of the following are present:

• The patient prefers a migraine-specific therapy after a balanced discussion of alternatives.
• Disability is substantial, and the patient values rapid movement to a well-tolerated option rather than serial titration through poorly matched drugs.
• A nonspecific oral preventive is a poor fit because of comorbidities, prior adverse-effect sensitivity, interaction burden, or adherence concerns.
• A monthly or quarterly schedule is more likely to be followed than a daily titrated regimen.
• The patient has chronic migraine, frequent migraine, or clinically important medication overuse and needs prevention integrated into a broader management plan.
• The patient accepts injection or infusion treatment, or prefers an oral gepant, and anticipated access is realistic.

An established oral preventive may still be the better first prescription when it provides a useful comorbidity match, has been effective before, is strongly preferred, or is substantially more affordable. ACP’s sequence is also reasonable when the patient fits its nonpregnant episodic-migraine population and places high value on avoiding higher drug costs. [2] That CGRP-targeted therapies are first-line eligible does not make every older option obsolete.

Step 3: Explain what the comparative evidence can and cannot prove

A network meta-analysis of 74 randomized trials involving 32,990 participants found that CGRP monoclonal antibodies and preventive gepants had favorable combinations of efficacy and tolerability compared with placebo and many established preventives. [8] Network comparisons are useful, but most treatment contrasts are indirect. They do not establish a universal rank order for every patient.

The strongest direct tolerability comparison is HER-MES, a double-anonymized phase 4 trial of erenumab versus topiramate. Discontinuation because of adverse events occurred in 10.6% of the erenumab group and 38.9% of the topiramate group. At least a 50% reduction in monthly migraine days was achieved in 55.4% and 31.2% of patients, respectively. [9] This supports erenumab’s comparative tolerability and effectiveness in that trial; it should not be generalized as a head-to-head result for every CGRP agent or every established preventive.

APPRAISE evaluated earlier erenumab use against physician-selected nonspecific oral preventives in adults with episodic migraine who had already failed one or two preventive treatments. At month 12, 56.2% of participants assigned erenumab versus 16.8% assigned oral preventives met a composite endpoint requiring continued treatment and at least a 50% reduction in monthly migraine days. Discontinuation because of adverse events occurred in 2.9% versus 23.3%. [10] The open-label design and prior-treatment-failure population limit claims about completely treatment-naive primary care patients.

Placebo-controlled trials also established preventive efficacy for daily atogepant and every-other-day rimegepant. [11,12] These trials support approved use. Still, they do not show that oral gepants are superior to monoclonal antibodies or identify a reliable biomarker for choosing one CGRP-targeted agent over another.

The evidence-based message is narrower than the marketing-style message: CGRP-targeted preventives are effective and often easier to continue, but individual response remains unpredictable and disease modification has not been established. [4,8]

Step 4: Match the route and drug to the patient

The current US preventive CGRP options include four monoclonal antibodies and two oral gepants. The monoclonal antibodies avoid the CYP3A4- and transporter-based dose adjustments required by the oral gepants, but they have longer persistence after dosing and route-specific logistics. Product labeling must be checked at each prescription and renewal because indications and warnings continue to change.

Table 2. Adult CGRP-targeted preventive options in primary care

Agent and route	Labeled preventive dose	Practical selection points
Erenumab-aooe (Aimovig), subcutaneous	70 mg once monthly; some patients may benefit from 140 mg once monthly. [13]	Receptor-directed monoclonal antibody. Simple monthly dosing. Ask specifically about constipation, blood pressure, and Raynaud symptoms.
Fremanezumab-vfrm (Ajovy), subcutaneous	Adults: 225 mg monthly or 675 mg every 3 months. The current label also includes 225 mg monthly for episodic migraine in patients 6-17 years old who weigh at least 45 kg. [14]	Monthly or quarterly choice. The pediatric indication is narrow; do not extrapolate adult or pediatric dosing outside the label.
Galcanezumab-gnlm (Emgality), subcutaneous	240 mg loading dose, given as two 120-mg injections, then 120 mg monthly. [15]	A loading dose may be appropriate when a clear starting point is desired. Injection-site reactions are common; current class warnings still apply.
Eptinezumab-jjmr (Vyepti), intravenous	100 mg every 3 months; some patients may benefit from 300 mg every 3 months. Infuse over approximately 30 minutes. [16]	Supervised quarterly infusion may help when self-injection is undesirable, but requires infusion access and hypersensitivity readiness.
Atogepant (Qulipta), oral	Episodic migraine: 10, 30, or 60 mg once daily. Chronic migraine: 60 mg once daily. [17]	Daily oral option for episodic or chronic migraine. Check CYP3A4 and OATP interactions, kidney function in severe impairment, and hepatic status. Constipation, nausea, fatigue or somnolence, decreased appetite, and weight decrease can occur.
Rimegepant (Nurtec ODT), oral	75 mg every other day for preventive treatment of episodic migraine. Maximum 75 mg in 24 hours; safety of more than 18 doses in 30 days has not been established. [18]	Oral dissolving tablet with both acute and preventive indications. Check CYP3A4 and P-gp interactions. Avoid in severe hepatic impairment and end-stage renal disease.

A practical route choice can often be made in one minute:

• Choose a monthly or quarterly monoclonal antibody when low interaction burden, infrequent dosing, or avoidance of daily tablets is a priority.
• Choose atogepant when the patient prefers a daily oral preventive or has chronic migraine and an oral route is favored.
• Choose rimegepant when every-other-day oral prevention for episodic migraine is attractive, and the acute-plus-preventive dosing plan can be documented clearly.
• Choose eptinezumab when an infusion model is acceptable and supervised administration is a benefit rather than a burden.

Do not choose based on brand familiarity alone. Formulary, dosing interval, prior response, constipation risk, blood pressure, vascular symptoms, kidney and liver function, interaction profile, pregnancy plans, and route preference can all change the decision.

Step 5: Use a 2026 safety screen, not a 2018 safety script

The current US labels for erenumab, fremanezumab, galcanezumab, and eptinezumab each include warnings for constipation with serious complications, new-onset or worsening hypertension, and Raynaud’s phenomenon, in addition to hypersensitivity precautions. [13-16] This is clinically important because some earlier summaries described these products mainly in terms of injection-site reactions and hypersensitivity.

Atogepant and rimegepant also carry postmarketing warnings for hypertension and Raynaud’s phenomenon. [17,18] Atogepant commonly causes constipation, but its label should not be represented as identical to the serious-constipation warning now present in the four monoclonal-antibody labels.

Table 3. Baseline safety checks and follow-up actions

Concern	Before prescribing	Follow-up action
Blood pressure	Record a reliable baseline value; review uncontrolled hypertension and recent medication changes.	Recheck early after initiation or a dose change in at-risk patients. Evaluate new or worsening hypertension and consider whether continued CGRP blockade is appropriate. [13-18]
Constipation and GI motility	Ask about baseline bowel frequency, prior severe constipation, obstruction, motility disorders, and constipating drugs.	Do not wait for routine follow-up when constipation is severe, persistent, or accompanied by pain, vomiting, or distension. Treat promptly and reassess the prevention. [13-17]
Raynaud or peripheral ischemic symptoms	Ask about cold- or stress-triggered color change, pain, numbness, ulcers, and known Raynaud’s phenomenon.	Evaluate new or worsening symptoms promptly and follow label-specific discontinuation advice. [13-18]
Hypersensitivity	Review prior serious reaction to the product or excipients.	Counsel on delayed and immediate reactions. Infusion settings need appropriate response capability. [13-18]
Pregnancy or preconception	Determine pregnancy status and near-term plans when relevant. Current labels do not establish safety in pregnancy.	Routine initiation during pregnancy or active preconception planning should move to an individualized obstetric or headache-specialist risk-benefit pathway. [3,13-18]
Kidney, liver, and interactions	Most relevant to oral gepants. Review kidney and hepatic function and the full medication list.	For atogepant, use the current interaction and renal dosing tables; chronic-migraine use is not recommended in severe renal impairment or end-stage renal disease. Avoid both oral gepants in severe hepatic impairment and avoid rimegepant in end-stage renal disease. [17,18]

A CGRP-targeted drug is not a vasoconstrictor in the way a triptan is, but that does not erase the postmarketing blood-pressure and Raynaud warnings. Avoid telling a patient that the class is “cardiovascular-risk free.” The label-based statement is that monitoring and individualized assessment remain necessary.

Step 6: Define the treatment trial before the first dose

Write down the baseline and the success threshold before treatment begins. Otherwise, continuation decisions become vulnerable to recall bias and payer renewal deadlines.

The IHS recommends evaluating most oral preventives and monthly injectable preventives after at least 3 months at an adequate or target dose. A quarterly monoclonal antibody generally requires a longer observation period, commonly 6 months, because that allows assessment after two scheduled doses. [3] Earlier safety review may be necessary, and a clearly intolerable or dangerous adverse effect is not a reason to complete an efficacy trial.

A practical follow-up plan is:

1. Early safety contact: Review blood pressure when relevant, bowel symptoms, Raynaud symptoms, hypersensitivity, administration problems, and adherence after initiation.
2. Formal efficacy assessment: Compare monthly migraine days, monthly headache days, acute-treatment days, disability, and the patient’s functional goal with baseline after an adequate trial.
3. Continuation threshold: A reduction of at least 50% in monthly migraine days is a common benchmark. In chronic migraine or after multiple failures, a 30% reduction plus a meaningful improvement in disability, acute-medication use, or function can still be clinically valuable. [3]
4. Renewal documentation: Record both the numeric change and the practical change, such as fewer missed workdays, less rescue medication, or restored activity.
5. Stop or switch when needed: Stop for a serious safety issue or an unacceptable adverse effect. If the response is inadequate after a valid trial, reassess the diagnosis, adherence, medication overuse, and treatment goal before switching.

Switching between CGRP monoclonal antibodies can be considered when the first agent is ineffective or poorly tolerated, but evidence is limited and largely observational. [3] Document a switch as an individualized trial, not a guaranteed class rescue. Combination preventive regimens and dual-CGRP strategies require a separate evidence and safety assessment and are outside this primary care framework.

Access remains a clinical implementation problem

A 2026 interrupted time-series analysis reviewed 149 commercial plan policies. 142 plans covered at least one preventive CGRP-targeted medication, but coverage of individual products ranged from 62.4% to 84.6%, and step therapy requirements remained largely in place 10 months after the AHS first-line statement. [19] Clinical first-line eligibility therefore does not guarantee first-prescription coverage.

A strong prior-authorization submission should include:

• Migraine diagnosis and episodic or chronic classification.
• Baseline monthly headache days, monthly migraine days, and acute-medication days.
• Disability or functional impact.
• Previous preventive trials, including dose, duration, response, and reason for discontinuation.
• Contraindications or poor-fit reasons for requested alternatives when relevant.
• The requested product, route, dose, and label indication.
• The patient-specific reason this therapy is preferred.
• The planned response measure and follow-up date.

A concise chart sentence can support both care and authorization: “Preventive treatment is indicated because the patient has X monthly migraine days with Y functional impact. The requested CGRP-targeted therapy was selected after shared decision-making because of Z patient-specific fit, with response to be assessed by monthly migraine days, acute-treatment days, and function after an adequate trial.”

When primary care should involve a headache specialist

Family physicians can initiate many CGRP-targeted preventives, but referral or consultation is appropriate when:

• The diagnosis is uncertain, the neurologic examination is abnormal, or secondary-headache warning features are present.
• Headache is chronic and refractory despite adequately documented preventive trials.
• Medication overuse is severe, complicated by opioids or barbiturate-containing products, or difficult to reverse.
• Pregnancy, active preconception planning, or lactation creates a difficult risk-benefit decision.
• There is uncontrolled hypertension, clinically important Raynaud’s phenomenon, peripheral ischemic disease, or a serious GI motility history.
• A pediatric patient falls outside a current labeled indication or needs a broader pediatric migraine plan. The current fremanezumab label includes episodic migraine prevention for patients 6-17 years old who weigh at least 45 kg, but that does not convert this adult framework into a pediatric protocol. [14]
• The proposed plan involves combination biologic therapy, onabotulinumtoxinA plus a CGRP-targeted drug, or other complex off-label prevention.

A one-visit family medicine prescribing framework

The entire decision can be organized into six questions:

1. Is this migraine, and is the phenotype episodic, chronic, or complicated by medication overuse?
2. Is prevention justified by frequency, disability, acute-treatment limitations, or patient preference?
3. Is a CGRP-targeted therapy first-line eligible and a better fit than an established oral option for this patient?
4. Which route and label best match the patient’s migraine pattern, comorbidities, interactions, and preferences?
5. Have blood pressure, constipation, Raynaud symptoms, hypersensitivity, pregnancy context, kidney or liver function, and drug interactions been addressed?
6. Are the baseline, success threshold, follow-up interval, and payer documentation already in the chart?

If all six answers are clear, the prescription is clinically defensible whether the final choice is a CGRP-targeted therapy or an established oral preventive.

 

 

References

1. Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey AD; American Headache Society. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update. Headache. 2024;64(4):333-341. DOI. PubMed. Accessed August 19, 2026.
2. Qaseem A, Cooney TG, Etxeandia-Ikobaltzeta I, et al; Clinical Guidelines Committee of the American College of Physicians. Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline From the American College of Physicians. Ann Intern Med. 2025;178(3):426-433. Current corrected record reviewed. DOI. PubMed. Accessed August 19, 2026.
3. Puledda F, Sacco S, Diener HC, et al. International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine. Cephalalgia. 2024;44(9):3331024241269735. DOI. PubMed. Accessed August 19, 2026.
4. Pozo-Rosich P, Caronna E, Sacco S, et al. Early treatment in migraine – A call to shift prevention from attacks to disease progression: A position statement from the International Headache Society. Cephalalgia. 2025;45(10):3331024251387721. DOI. PubMed. Accessed August 19, 2026.
5. Headache Classification Committee of the International Headache Society. 1.1 Migraine without aura. International Classification of Headache Disorders, 3rd edition. Official source. Accessed August 19, 2026.
6. Headache Classification Committee of the International Headache Society. 1.3 Chronic migraine. International Classification of Headache Disorders, 3rd edition. Official source. Accessed August 19, 2026.
7. Headache Classification Committee of the International Headache Society. 8.2 Medication-overuse headache. International Classification of Headache Disorders, 3rd edition. Official source. Accessed August 19, 2026.
8. Lampl C, MaassenVanDenBrink A, Deligianni CI, et al. The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain. 2023;24(1):56. DOI. PubMed. Accessed August 19, 2026.
9. Reuter U, Ehrlich M, Gendolla A, et al. Erenumab versus topiramate for the prevention of migraine – a randomized, double-blind, active-controlled phase 4 trial. Cephalalgia. 2022;42(2):108-118. DOI. PubMed. PMC. Accessed August 19, 2026.
10. Pozo-Rosich P, Dolezil D, Paemeleire K, et al. Early Use of Erenumab vs Nonspecific Oral Migraine Preventives: The APPRAISE Randomized Clinical Trial. JAMA Neurol. 2024;81(5):461-470. Current corrected article reviewed. DOI. PubMed. PMC. Accessed August 19, 2026.
11. Ailani J, Lipton RB, Goadsby PJ, et al. Atogepant for the Preventive Treatment of Migraine. N Engl J Med. 2021;385(8):695-706. DOI. PubMed. Accessed August 19, 2026.
12. Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomized, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51-60. DOI. PubMed. Accessed August 19, 2026.
13. DailyMed. AIMOVIG (erenumab-aooe) injection, prescribing information. National Library of Medicine. Updated July 14, 2026; labeling revised March 2025. Official source. Accessed August 19, 2026.
14. DailyMed. AJOVY (fremanezumab-vfrm) injection, prescribing information. National Library of Medicine. Updated June 5, 2026; labeling revised June 2026. Official source. Accessed August 19, 2026.
15. DailyMed. EMGALITY (galcanezumab-gnlm) injection, prescribing information. National Library of Medicine. Labeling revised June 2026. Official source. Accessed August 19, 2026.
16. DailyMed. VYEPTI (eptinezumab-jjmr) injection, prescribing information. National Library of Medicine. Labeling revised June 2026. Official source. Accessed August 19, 2026.
17. DailyMed. QULIPTA (atogepant) tablets, prescribing information. National Library of Medicine. Labeling revised September 2025. Official source. Accessed August 19, 2026.
18. DailyMed. NURTEC ODT (rimegepant sulfate) orally disintegrating tablets, prescribing information. National Library of Medicine. Labeling revised April 2026. Official source. Accessed August 19, 2026.
19. Moskatel LS, Slusky DJG. The state of insurance coverage of calcitonin gene-related peptide-targeted medications and its impact on the implementation of the American Headache Society’s 2024 consensus statement: An interrupted time-series analysis. Headache. 2026;66(4):801-812. DOI. PubMed. Accessed August 19, 2026.